Oncology Therapies and blood transfusions Flashcards

1
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How do we decide what to use?

A
  • Clinical trials for all cancer types
  • Target specific molecular pathways when possible
  • Old chemotherapy agents can be helpful but also toxic!
  • Initial and acquired drug resistance continues to be challenging!
    Impaired membrane transport of drugs
    Enhanced drug metabolism
    Mutated target proteins
    Blockage of apoptosis due to mutations in cellular proteins
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Antiemetic medications

A
  • 5HT3 receptor antagonists IV/PO/Sublingual
    Ondansetron (Zofran)
    Palonosetron (Aloxi)
    May cause QT prolongation
  • NK1 receptor antagonists (Preventative) IV/PO
    Aprepitant (Emend)
    Given with Dexamethasone to improved immediate and delayed effect

Can’t swallow?
Prochlorperazine (Compazine) rectally

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

GI Toxicity

Oral mucositis

A

Pretreatment dental care
Ice chips during infusion (5-FU)
Antifungal medication
Antiviral medication
Mouthwashes
Non alcohol rinses (Biotene)
Lidocaine
Pain control!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

GI Toxicity

Diarrhea Tx

mild/moderate/severe

A

Diarrhea
Mild-moderate
Loperamide (Imodium)

Severe
IV hydration
Electrolyte replacement
Octreotide (Sandostatin) SC inj. up to TID
Inhibits multiple hormones (growth hormone, glucagon, insulin, LH, and VIP)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Skin toxicity

S/Sx

A

Hyperpigmentation
Alopecia
Photosensitivity
Nail changes
Acral erythema (hand foot syndrome)
Painful palms or soles with erythema progressing to blisters, desquamation, and ulceration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Cardiac toxicity

S/Sx

acute/subacute/delayed

A

Acute: During chemotherapy treatment
Subacute: Days to months after
Delayed: Years after treatment
Possible baseline testing
Echocardiogram to ensure EF > 50%
EKG

Arrhythmias
Cardiac ischemia
Myocarditis
Thrombosis
Heart failure risk
Total dose received
Age > 70
Chest irradiation
Preexisting cardiac disease
Multiple agents at risk for cardiac complications

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Cisplatin

Nephrotoxicity

A

IV hydration before, during, and after chemotherapy administration
Monitor Cr+ and electrolytes
May also develop low mg+, K+, and Na+

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Miscellaneous toxicity

Hemorrhagic cystitis

A

peeing blood

Drink lots of fluids!
Frequent urination
IV Mesna for prevention

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Miscellaneous toxicity

Neuropathy S/Sx

A

Sensory
Motor
Autonomic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

If toxicity occurs, what do we do?

A

Hold next cycle until symptoms resolve
Add supportive medications
Drug dose reduction
Palliation vs. cure
Change regimen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Intravesical therapy

general and Sx

A

Deliver medications directly into the bladder via a urethral catheter
Typically post transurethral resection to decrease likelihood of recurrence

Side effects
Irritative voiding symptoms
Hemorrhagic cystitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

targeted agents

most common types

A

Many medications treating many cancer subtypes

Most common
* Monoclonal antibodies
Rituximab (Rituxan)
* Kinase inhibitors
Ibrutinib (Imbruvica)

Side effects differ based on cell receptor acts on

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

immunotherapy

general and types

4

A

Using own immune system

Types
* Immune checkpoint therapy
Help T cells respond longer
Ipilimumab (Yervoy) for lung cancer
* Adoptive cell therapy
Chimeric antigen cell (CAR) T cell therapy- T cells that are all genetically engineered to find and fight the cancer are infused
Multiple types undergoing clinical trials!
* Cytokine therapy
Interferons and interleukins are infused/injected, trigger an immune response
May be combined with other immunotherapies
IL-2 therapy for renal cancer
* Vaccine therapy
Help the body recognize cancer cells and stimulate the immune system
Sipuleucel-T (Provenge)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Blood Transfusions

Blood Types

A

Four Major Groups
A
B
AB
O

Blood types are inherited
Antigen is present on the RBC
Typing is done w/rbc

Antibody is present in the plasma
Antibody screening done on plasma

43% of population are O, 42% A, 12% B and 3% AB

19
Q

Blood Types

O negative

A

Universal donor
It carries no antigen

20
Q

Blood types

AB positive

A

Universal recipient
It carries no antibodies in the plasma

21
Q

Rh Factor

general

A

Found on the surface of an RBC
Can be phenotypically positive or negative
Positive is dominant over negative

Rh negative patients form antibodies against the Rh factor if they are exposed to Rh positive blood

Blood transfusion between incompatible groups causes an immune response against the cells carrying the antigen Resulting in transfusion reaction

22
Q

Rh Incompatibility in Pregnancy

A

Occur when the mother is Rh- and the baby is Rh+
Treatment:
Give a series ofRhoGAMshots during pregnancy to all Rh- mothers
1st shot: around the 28th week of pregnancy
2nd shot: just after birth

24
Q

RBC Transfusion

Indications

A

Acute Blood Loss
Symptomatic Anemia
Volume: 300mL
1 unit UP Hgb 1 g/dL
Consider transfusion for Hgb < 7g/dL

25
26
indications for whole, packed RBCs, and autologous
Whole blood Used for cardiac surgery or massive hemorrhage (>10 units of blood are needed in 24-hours) Packed red blood cells Most commonly used Recommended transfusion “trigger” - hemoglobin is 7-8 g/dL Autologous red blood cells Donate own blood for an elective procedure
27
# Platelet Transfusions indications and how much will it increase platelet count?
Risk of spontaneous bleeding Platelet count < 80,000/mcL Risk of life-threatening bleeding Platelet count < 5,000/mcL 6 pack or 1 unit pheresed platelets 1 pheresed unit will increase count by 50,000-60,000/mcL Lasts 2-3 days
28
Platelet Transfusion Goals
29
Fresh Frozen Plasma
200-250 ml of plasma containing All clotting factors (1 unit/mL of each) AT-III Protein C & S Indications: Correct factor deficiencies Thrombotic microangiopathies- TTP Correct/prevent coagulopathy with massive transfusions- 1:2 FFP:PRBC
30
Cryoprecipitate
Cryoprecipitated antihemophilic factor (AHF) Thaw FFP and precipitate refrozen 15-20 ml per unit (bag) Fibrinogen >150 mg Factor VIII > 80 IU Factor XIII at least 50-75 IU Von Willebrand Factor at least 100-150 IU Indications Acute DIC Low fibrinogen with bleeding/risk 1 unit INCREASE fibrinogen 8mg/dL
31
Transfusion Complications
Volume overload Transfusion reactions Iron overload Infections Hyperkalemia Massive transfusions CKD
32
# Transfusion Rxns
33
# Acute Transfusion Reactions minor and critical
Complication that occurs during or after a blood product is given Range from clinically benign to life-threatening Minor Urticarial (simple allergic) transfusion reaction Febrile non-hemolytic transfusion reaction Critical Transfusion-associated circulatory overload (TACO) Transfusion-related acute lung injury (TRALI) Acute hemolytic transfusion reaction (AHTR) Transfusion-associated sepsis Anaphylactic transfusion reaction q
34
# Minor transfusion rxn Urticarial transfusion reaction (UTR)
Common reaction Occurs during or up to 2 hours after the transfusion Commonly due to an antigen-antibody interaction that occurs between the patient and the product given Clinical features: Hives or pruritus Management: Mild reaction – continue the transfusion Antihistamines (H1 and H2 blockers)
35
# Minor transfusion rxn Febrile non-hemolytic transfusion reaction (FNHTR)
Febrile non-hemolytic transfusion reaction (FNHTR) Occurs during and up to 4 hours after transfusion Accumulation of cytokines in the donor blood → immune reaction Type II hypersensitivity reaction in which the host antibodies target donor leukocytes Prevention by giving leukoreduced blood products Clinical features: Low-grade fever with chills Headache Malaise Management: Hold the transfusion for 30 minutes (often can restart) Acetaminophen for fever Check CBC and bilirubin to rule out hemolytic reaction
36
# critical transfusion rxn Transfusion-associated circulatory overload (TACO)
Transfusion-associated circulatory overload (TACO) Occurs during or within 6 hours after transfusion Patient develops pulmonary edema due to volume overload or circulatory overload < 1% of patients At risk patients: Receive a large volume of a transfused product over a short period of time H/O renal or cardiovascular disease Clinical features: Sudden tachycardia Hypertension Overload symptoms: increased jugular venous pressure CXR: bilateral infiltrates (pulmonary edema) Management: Stop the transfusion Diuresis – furosemide (Lasix) Supplemental oxygen or assisted ventilation
37
# critical transfusion rxn Transfusion-related acute lung injury (TRALI)
Transfusion-related acute lung injury Occurs during or up to 6 hours after transfusion Patients develop acute lung injury HLA antibodies in the donor blood triggers the neutrophils and pulmonary endothelial cells of the recipient Neutrophils secrete proteolytic enzymes that lead to tissue damage → hypoxemia 1 in 5,000 transfusions Clinical features: Fever and/or chills Respiratory distress (tachypnea, frothy pink sputum) Hypotension CXR: bilateral infiltrates (pulmonary edema) Management: Stop the infusion Assisted ventilation or oxygen administration IV steroids to aid with inflammation No diuresis
38
# critical transfusion rxn Acute hemolytic transfusion reaction (AHTR) General
Acute hemolytic transfusion reaction (AHTR) True EMERGENCY Occurs during or within 1 hour after transfusion Acute intravascular hemolysis of transfused RBCs Usually due to ABO incompatibility Mislabeling and administering to wrong person 1:76,000 transfusions
39
# Acute hemolytic transfusion reaction (AHTR) Clin man
High grade fever Flank pain, hematuria Tachycardia, Tachypnea, Hypotension Oozing from the IV site (DIC) Chills Headache Anxiety Cardiovascular collapse
40
Response to Suspected Hemolytic Reaction
Stop Transfusion Aggressive intravenous hydration urine output to be 100-200 cc/hr Prevent acute tubular necrosis Confirm correct transfusion was initiated Return blood, bag, tubing, labels, transfusion record to the blood bank Retype and crossmatch **Check Coombs test** → should be positive Coagulation studies (PT, PTT, Fibrinogen)- Risk of DIC DIC: Administer FFP and platelets
41
Transfusion-associated sepsis
Rare reaction Usually occurs within 1 hour of transfusion Bacterial infection from a transfusion product that contains a microorganism Clinical features: Fever and/or chills Hypotension Management: Stop the infusion Culture the recipient’s blood and the donor’s blood Broad-spectrum antibiotics
42
Anaphylactic transfusion reaction | clin man and Tx
Usually occurs right after the start of the transfusion; can be delayed up to 4 hours Clinical features: Angioedema Wheezing, respiratory distress (bronchospasm) Hypotension Nausea and/or vomiting Cardiac arrest or shock Management: Stop the transfusion Hemodynamic stabilization (IV fluids, vasopressors) Airway management Epinephrine, steroids, antihistamines